4.7 Article

Microfluidic Arrays of Breast Tumor Spheroids for Drug Screening and Personalized Cancer Therapies

期刊

ADVANCED HEALTHCARE MATERIALS
卷 11, 期 1, 页码 -

出版社

WILEY
DOI: 10.1002/adhm.202101085

关键词

breast cancer; cancer; drug testing; microfluidics; personalized medicine; preclinical models; spheroids

资金

  1. Princess Margaret Living Biobank
  2. Natural Sciences and Engineering Research Council (NSERC Canada)
  3. New Frontiers in Research Fund
  4. NSERC Canada Graduate Scholarship
  5. NSERC CREATE Training Program in Organ-on-aChip Engineering and Entrepreneurship (TOeP) [482073-2016]
  6. Ontario Graduate Scholarship (OGS)

向作者/读者索取更多资源

The study introduces a novel microfluidic platform for efficient studies on the effect of drug dose and supply rate on chemosensitivity of breast tumor spheroids, and demonstrates the capability to grow large arrays of tumor spheroids from patient-derived cells of different breast cancer subtypes.
One of the obstacles limiting progress in the development of effective cancer therapies is the shortage of preclinical models that capture the dynamic nature of tumor microenvironments. Interstitial flow strongly impacts tumor response to chemotherapy; however, conventional in vitro cancer models largely disregard this key feature. Here, a proof of principle microfluidic platform for the generation of large arrays of breast tumor spheroids that are grown under close-to-physiological flow in a biomimetic hydrogel is reported. This cancer spheroids-on-a-chip model is used for time- and labor-efficient studies of the effects of drug dose and supply rate on the chemosensitivity of breast tumor spheroids. The capability to grow large arrays of tumor spheroids from patient-derived cells of different breast cancer subtypes is shown, and the correlation between in vivo drug efficacy and on-chip spheroid drug response is demonstrated. The proposed platform can serve as an in vitro preclinical model for the development of personalized cancer therapies and effective screening of new anticancer drugs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据